C000245561 Fees and Costs — Amplify Treatments, Testing and Advancements ETF
Data updated: 2024-08-27
The net expense ratio is 0.68%. There are no sales loads or redemption fees. Portfolio turnover was 55%.
C000245561 Fees and Expenses
Annual operating expenses and sales charges of C000245561. Prospectus, as of January 31, 2024.
| Annual operating expenses | |
|---|---|
| Management fee | 0.68% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.00% |
| Gross expense ratio | 0.68% |
| Fee waiver | — |
| Net expense ratio | 0.68% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
C000245561 Costs Over Time
On $10,000 invested in C000245561, assuming 5% a year before costs, total costs come to $428 over 5 years, cutting the return by 0.71% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.68%) | $71 | $224 | $389 |
| Lost growth on money paid in costs | $0 | $11 | $39 |
| Total costs | $71 | $235 | $428 |
| Value after costs | $10,429 | $11,342 | $12,335 |
| Impact on return, per year | 0.71% | 0.71% | 0.71% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.